Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31588133 | 1.00 | CLK4 (0.61) | CLK4AURKAGSK3AGSK3BGRM5 | |
| SCHEMBL25543819 | 0.88 | AURKA (0.51) | CLK4AURKAGSK3AGSK3BGRM5 | |
| SCHEMBL27787243 | 0.87 | CLK4 (0.63) | CLK4IDO1MAOBGABRA1GABRG2 | |
| Hydrochloric Acid SCHEMBL28684505 | 0.87 | GRM5 (0.59) | CLK4AURKAGSK3AGSK3BGRM5 | |
| Hydrochloric Acid SCHEMBL28007259 | 0.85 | CLK4 (0.61) | CLK4IDO1MAOBGABRA1GABRG2 | |
| SCHEMBL2154026 | 0.85 | CLK4 (0.65) | CLK4IDO1MAOBGABRA1GABRG2 | |
| SCHEMBL29425207 | 0.83 | GABRG2 (0.61) | CLK4IDO1MAOBGABRA1GABRG2 | |
| SCHEMBL270874 | 0.83 | GABRG2 (0.61) | CLK4IDO1MAOBGABRA1GABRG2 | |
| SCHEMBL13977114 | 0.83 | CDC7 (0.59) | CLK4AURKAGSK3AGSK3BGRM5 | |
| SCHEMBL7607470 | 0.81 | KIT (0.51) | CLK4AURKAGSK3AGSK3BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-29 | — | — | US | claimed |
| JP-4851440-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| EP-1723140-B1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-11-04 | — | — | EP | claimed |
| CN-101429194-A | Process for the preparation of tryptase inhibitors | AVENTIS PHARMA INC (US) | 2009-05-13 | — | — | CN | claimed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | claimed |
| CN-1950362-A | Preparation method of tryptase inhibitor | AVENTIS PHARMA INC (US) | 2007-04-18 | — | — | CN | claimed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| EP-1571150-A1 | Process for the preparation of tryptase inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | claimed |
| CN-120028308-A | Small molecule Raman probe, bar code probe, encoding method and application thereof | 北京大学 | 2025-05-23 | — | — | CN | disclosed |
| EP-3604308-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3604308-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2020-02-05 | — | — | EP | disclosed |
| US-9657015-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-23 | — | — | US | disclosed |
| WO-2016016364-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1571150-A1 | Process for the preparation of tryptase inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-5064832-A | Bipyrimidine Compounds, Antitumor Agents | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| US-4968804-A | Bipyridine compounds | CIBA-GEIGY CORPORATION (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0350448-A1 | Biaryl compounds | CIBA-GEIGY AG (CH) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | CLK4 4316/4885AURKA 2918/4885GSK3A 2713/4885 |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | CMA1, TPSAB1, TPSB2 | CLK4 4316/4885AURKA 2918/4885GSK3A 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.